Last reviewed · How we verify
NCT00634205
A Phase II Study Assessing the Activity of Valproate Acid Plus Doxorubicin in Refractory or Recurrent Malignant Mesothelioma
Phase 2 trial testing Valproate plus doxorubicin in Malignant Mesothelioma in 45 participants. Completed in 1 June 2010.
1 March 2009
Quick facts
| Lead sponsor | European Lung Cancer Working Party |
|---|---|
| Phase | Phase 2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 45 |
| Start date | 1 July 2006 |
| Primary completion | 1 March 2009 |
| Estimated completion | 1 June 2010 |
| Sites | 8 locations across Belgium, France |
Drugs / interventions tested
- Valproate plus doxorubicin — full drug profile →
Conditions studied
- Malignant Mesothelioma — all drugs for Malignant Mesothelioma →
Sponsor
European Lung Cancer Working Party — full company profile →
Who can join
18 and older, any sex, with Malignant Mesothelioma. Patients with the condition only — healthy volunteers not accepted.
What's being measured
Primary outcomes are the specific endpoints the trial is designed to prove or disprove.
-
Response rate
Time frame: Every 3 courses
Sponsor's own description
The purpose of this study is to determine the response rate to the combination of doxorubicin and valproate acid in patients with MM failing after at least one previous chemotherapy regimen including platinum derivatives .
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials.
Cheng Y, He C, Wang M, Ma X, et al · · 2019 · cited 760× · PMID 31871779 · DOI 10.1038/s41392-019-0095-0 -
Exploring the Drug Repurposing Versatility of Valproic Acid as a Multifunctional Regulator of Innate and Adaptive Immune Cells.
Soria-Castro R, Schcolnik-Cabrera A, Rodríguez-López G, Campillo-Navarro M, et al · · 2019 · cited 43× · PMID 31001564 · DOI 10.1155/2019/9678098
Verify or expand the search:
- PubMed search for NCT00634205
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Malignant Mesothelioma
Currently open trials in the same condition.
- NCT06566079 — Study of ISM6331 in Participants With Advanced/Metastatic Malignant Mesothelioma or Other Solid Tumors · Phase 1 · recruiting
- NCT06057935 — A Study of Additional Chemotherapy After Surgery for People With Malignant Peritoneal Mesothelioma · Phase 2 · recruiting
- NCT03007030 — Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery · Phase 2 · recruiting
Other European Lung Cancer Working Party trials
Trials by the same sponsor.
- NCT03368820 — Cardiovascular Morbidities and Lung Cancer Treatment: a Prospective Registry · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT00634205 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by European Lung Cancer Working Party
- Last refreshed: 11 February 2015
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00634205.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing